BioSpace News Archive

Portage Biotech Inc. announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601 ( NCT04969315 ).

Clene Inc. today announced that The Lancet’s journal eClinicalMedicine has published combined detailed analyses of the Phase 2 RESCUE-ALS study and its open-label extension trial.

AVITA Medical, Inc. announced that it has rejoined the broad-market Russell 3000® Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Ovid Therapeutics Inc. today announced that the company was added to the Russell 3000 ® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.

Fractyl Health, an organ-editing metabolic therapeutics company pioneering novel treatments for type 2 diabetes, unveiled compelling 48-week results from the open-label phase of the ongoing Revitalize 1 pivotal study at the American Diabetes Association’s 83rd Scientific Sessions.

Emulate, Inc., the leading provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.

Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, announces it has appointed Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer.

Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that it has raised over £5 million in an over-subscribed Series A financing round.

May Health announced new clinical trial results providing preliminary data supporting the safety and effectiveness of its Ovarian Rebalancing™ treatment for inducing ovulation in women with PCOS-related infertility.

Biora Therapeutics, Inc. shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model,” which were presented during the American Diabetes Association 83rd Scientific Sessions, held June 23–26, 2023 in San Diego, California.